BYND STOCK LOSS: Beyond Meat, Inc. Faces Securities Fraud Class Action Investigation due to Impairment Charge – Contact BFA Law if You Suffered Losses

BYND STOCK LOSS: Beyond Meat, Inc. Faces Securities Fraud Class Action Investigation due to Impairment Charge – Contact BFA Law if You Suffered Losses GlobeNewswire November 17, 2025 NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Beyond Meat, Inc. (NASDAQ: BYND) for […]

Iron Cap Group Introduces Next-Generation Market Access Engine for Rapid Activation

PARIS, Nov. 17, 2025 (GLOBE NEWSWIRE) — Iron Cap Group today unveiled its next-generation Market Access Engine, a system developed to minimize latency between account creation and market entry. The technology incorporates automated approval routing, intelligent verification layers, and load-optimized infrastructure to handle large user volumes with minimal processing time. “Our technology delivers immediate responsiveness,”

Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology

— Olutasidenib continued to demonstrate durable efficacy and a manageable safety profile in a broad range of patients with R/R mIDH1 AML, including those previously treated with venetoclax-based regimens — Rigel advances its strategic collaborations to further evaluate olutasidenib with the activation of a fifth study with MD Anderson and enrollment of the first patient

PRA Group to Participate in Upcoming Investor Events

PRA Group, Inc. (Nasdaq: PRAA) (the “Company”), a global leader in acquiring and collecting nonperforming loans, announced today that management is scheduled to participate at the following investor events: https://mma.prnewswire.com/media/819349/PRA_Logo.jpg The Citizens Financial Services ConferenceDate: Tuesday, November 18, 2025Format: 1×1 and small group meetings onlyLocation: Lotte New York Palace, New York, New YorkCompany Participants: President

Biotheryx Announces Completion of Enrollment in Phase 1a Clinical Trial of BTX-9341 for the Treatment HR+/HER2- Breast Cancer

Topline data readout from Phase 1a clinical trial expected in Q1 2026 Biotheryx, Inc., a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory diseases, today announced the completion of enrollment in the ongoing Phase 1a clinical trial of BTX-9341, a potent and selective CDK4/6 degrader, for the

New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis

First-line treatment with TREMFYA® shows significant inhibition of radiographic progression at Week 24, which was sustained through Week 48, preserving joint health with a well-established safety profile More than half of TREMFYA®-treated patients across both dose groups achieved a 50% improvement in signs and symptoms of psoriatic arthritis by Week 48 in the Phase 3b

Airsys Unveils PowerOne™ AI-Era Cooling Solutions for Modern Data Centers

Intelligent, scalable cooling platforms address power density challengesdriven by AI, high-performance computing, and big data demands Airsys Cooling Technologies Inc., a global leader in mission-critical cooling solutions, today announced the launch of PowerOne, an intelligent, high-efficiency cooling solution that addresses the unprecedented data center cooling demands presented by the rise in usage of AI, hyperscale,

Financial Advisor Shawna Vanaken Moves from Commonwealth to Cetera’s Avantax Community of Tax-Focused Financial Professionals

Oregon-based Pinnacle Tax & Financial Services chooses Avantax for its tax expertise and growth resources Cetera welcomes longtime Commonwealth financial advisor Shawna Vanaken, CFP®, CPA, EA, who has joined Cetera's community of tax-focused financial professionals – Avantax. Vanaken and her team at Pinnacle Tax & Financial Services, LLC, in Beaverton, Oregon, oversee approximately $49 million

Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs

~Funding supports Phase 3 clinical development of PF614 and continued innovation in abuse- and overdose-resistant analgesics~ SAN DIEGO, CA / ACCESS Newswire / November 17, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC)("Ensysce" or the "Company"), pioneering novel solutions for severe pain with built-in abuse and overdose protection, today announced the closing of a $4 million convertible

Scroll to Top